Malaysian Healthcare May Benefit from Medical Tourism, Biopharma Push -- Market Talk

Dow Jones

02/19

0158 GMT - The Malaysian healthcare sector may benefit from high-acuity medical tourism and more self-sufficient biopharmaceutical manufacturing and distribution this year, MBSB Research says in a note. The outlook is supported by an aging population, rising demand for precision treatments and government incentives for both public and private healthcare providers, it says. Ongoing digitalization and adoption of artificial intelligence in hospital administration and medical equipment should also enhance efficiency, it says. However, downside risks remain, including increases in medical costs, potential shifts in drug policies and pricing pressures stemming from global trade tariffs, it adds. MBSB maintains a positive rating on the Malaysian healthcare sector.(yingxian.wong@wsj.com)

(END) Dow Jones Newswires

February 18, 2026 20:58 ET (01:58 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2612475661"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612475661\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612475661?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-19 09:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612475661","market":"sg","top_or_hot":-1,"title":"Malaysian Healthcare May Benefit from Medical Tourism, Biopharma Push -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0158 GMT - The Malaysian healthcare sector may benefit from high-acuity medical tourism and more self-sufficient biopharmaceutical manufacturing and distribution this year, MBSB Research says in a note. The outlook is supported by an aging population, rising demand for precision treatments and government incentives for both public and private healthcare providers, it says. Ongoing digitalization and adoption of artificial intelligence in hospital administration and medical equipment should also enhance efficiency, it says. However, downside risks remain, including increases in medical costs, potential shifts in drug policies and pricing pressures stemming from global trade tariffs, it adds. MBSB maintains a positive rating on the Malaysian healthcare sector.(yingxian.wong@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 18, 2026 20:58 ET (01:58 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Malaysian Healthcare May Benefit from Medical Tourism, Biopharma Push -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMalaysian Healthcare May Benefit from Medical Tourism, Biopharma Push -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-02-19 09:58</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0158 GMT - The Malaysian healthcare sector may benefit from high-acuity medical tourism and more self-sufficient biopharmaceutical manufacturing and distribution this year, MBSB Research says in a note. The outlook is supported by an aging population, rising demand for precision treatments and government incentives for both public and private healthcare providers, it says. Ongoing digitalization and adoption of artificial intelligence in hospital administration and medical equipment should also enhance efficiency, it says. However, downside risks remain, including increases in medical costs, potential shifts in drug policies and pricing pressures stemming from global trade tariffs, it adds. MBSB maintains a positive rating on the Malaysian healthcare sector.(yingxian.wong@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 18, 2026 20:58 ET (01:58 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持倉","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2612475661","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612475661","pubTimestamp":1771466280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0158 GMT - The Malaysian healthcare sector may benefit from high-acuity medical tourism and more self-sufficient biopharmaceutical manufacturing and distribution this year, MBSB Research says in a note. The outlook is supported by an aging population, rising demand for precision treatments and government incentives for both public and private healthcare providers, it says. Ongoing digitalization and adoption of artificial intelligence in hospital administration and medical equipment should also enhance efficiency, it says. However, downside risks remain, including increases in medical costs, potential shifts in drug policies and pricing pressures stemming from global trade tariffs, it adds. MBSB maintains a positive rating on the Malaysian healthcare sector.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4581":"高盛持仓","XBI":"SPDR S&P Biotech ETF","BK4585":"ETF&股票定投概念","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","XLV":"健康照护类股ETF-SPDR","LABU":"三倍做多标普生物-Direxion","BK4137":"综合支持服务","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","BK4588":"碎股","HCSG":"Healthcare Svcs Group Inc"},"translate_title":"马来西亚医疗保健可能受益于医疗旅游和生物制药的推动——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XLV":1.5,"LABU":0.6,"HCSG":1.5,"XBI":0.6},"content_text":"0158 GMT - The Malaysian healthcare sector may benefit from high-acuity medical tourism and more self-sufficient biopharmaceutical manufacturing and distribution this year, MBSB Research says in a note. The outlook is supported by an aging population, rising demand for precision treatments and government incentives for both public and private healthcare providers, it says. Ongoing digitalization and adoption of artificial intelligence in hospital administration and medical equipment should also enhance efficiency, it says. However, downside risks remain, including increases in medical costs, potential shifts in drug policies and pricing pressures stemming from global trade tariffs, it adds. MBSB maintains a positive rating on the Malaysian healthcare sector.(yingxian.wong@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2026 20:58 ET (01:58 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}